Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Damayanti Kerai
HSBC
Damayanti Kerai
HSBC
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-14.2%
Average Return
0 of 1 calls profitable · -40.0% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 0% of Damayanti Kerai's ratings turned a profit when each position was held for 1 year — averaging -14.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 8 Hold 5 Sell
Damayanti's Stock Coverage 20 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
IN:ZYDUSLIFE
Zydus Lifesciences Limited
 Oct 14, 2025 HOLD Strong Buy
-10.1% avg upside
2 analysts
$965.00
10.06% Downside
 ·
IN:APLLTD
Alembic Pharmaceuticals Limited
 Oct 14, 2025 HOLD Hold
+22.6% avg upside
1 analyst
$915.00
22.61% Upside
 ·
IN:AUROPHARMA
Aurobindo Pharma Ltd
 Oct 14, 2025 BUY Strong Buy
-11.3% avg upside
1 analyst
$1300.00
11.29% Downside
 ·
IN:BIOCON
Biocon Limited
 Oct 14, 2025 BUY Strong Buy
+5.0% avg upside
1 analyst
$435.00
4.99% Upside
 ·
IN:CIPLA
Cipla Ltd
 Oct 14, 2025 BUY Strong Buy
+30.2% avg upside
1 analyst
$1765.00
30.22% Upside
 ·
IN:DIVISLAB
Divi's Laboratories Limited
 Oct 14, 2025 BUY Strong Buy
+9.6% avg upside
1 analyst
$7400.00
9.59% Upside
 ·
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
 Oct 14, 2025 BUY Strong Buy
+14.8% avg upside
1 analyst
$1450.00
14.84% Upside
 ·
IN:GLENMARK
Glenmark Pharmaceuticals Limited
 Oct 14, 2025 BUY Strong Buy
+8.6% avg upside
1 analyst
$2370.00
8.59% Upside
 ·
IN:LUPIN
Lupin Limited
 Oct 14, 2025 BUY Strong Buy
+0.4% avg upside
1 analyst
$2340.00
0.39% Upside
 ·
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
 Oct 14, 2025 BUY Strong Buy
+5.6% avg upside
1 analyst
$1935.00
5.56% Upside
 ·
IN:ALKEM
Alkem Laboratories Ltd.
 Oct 14, 2025 HOLD Hold
-9.3% avg upside
1 analyst
$4850.00
9.31% Downside
 ·
IN:NH
Narayana Hrudayalaya Ltd.
 Oct 09, 2025 SELL Strong Sell
-17.8% avg upside
1 analyst
$1540.00
17.80% Downside
 ·
IN:RAINBOW
Rainbow Childrens Medicare Limited
 Oct 09, 2025 BUY Strong Buy
+7.7% avg upside
1 analyst
$1550.00
7.67% Upside
 ·
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
 Oct 09, 2025 BUY Strong Buy
+5.1% avg upside
1 analyst
$8870.00
5.12% Upside
 ·
IN:ASTERDM
Aster DM Healthcare Ltd.
 Oct 09, 2025 BUY Strong Buy
-5.8% avg upside
1 analyst
$750.00
5.81% Downside
 ·
IN:KIMS
Krishna Institute of Medical Sciences Limited
 Oct 09, 2025 BUY Strong Buy
+1.4% avg upside
1 analyst
$810.00
1.43% Upside
 ·
IN:MEDANTA
Global Health Limited
 Aug 11, 2025 SELL Strong Sell
-5.5% avg upside
1 analyst
$1200.00
5.50% Downside
 ·
IN:IPCALAB
IPCA Laboratories Limited
 Jul 17, 2025 HOLD Hold
-14.1% avg upside
1 analyst
$1375.00
14.07% Downside
 ·
IN:MAXHEALTH
Max Healthcare Institute Ltd
 Jul 17, 2025 HOLD Hold
+5.3% avg upside
1 analyst
$1145.00
5.30% Upside
 ·
RDY
Dr Reddy's Laboratories
 Jun 05, 2025 BUY Buy
+27.2% avg upside
2 analysts
$16.90
27.17% Upside
 -14.2%
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Damayanti Kerai — Frequently Asked Questions
How accurate are Damayanti Kerai's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Damayanti's ratings were profitable over a one-year hold, with an average return of -14.2% per rating, or -40.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Damayanti ranked on 13Foresight?
Damayanti Kerai is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Damayanti cover?
Damayanti most recently has ratings on IN:ZYDUSLIFE, IN:APLLTD, IN:AUROPHARMA, IN:BIOCON, IN:CIPLA, IN:DIVISLAB, IN:DRREDDY, IN:GLENMARK, IN:LUPIN, IN:SUNPHARMA, IN:ALKEM, IN:NH and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.